{
    "root": "23ebfa5b-992a-4847-b6d3-8d62da976ba8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ojjaara",
    "value": "20230915",
    "ingredients": [
        {
            "name": "MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE",
            "code": "LDX8893L5D"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A CORN",
            "code": "AG9B65PV6B"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "PROPYL GALLATE",
            "code": "8D4SNN7V92"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "ojjaara indicated treatment intermediate high-risk myelofibrosis ( mf ) , including primary mf secondary mf [ post-polycythemia vera ( pv ) post-essential thrombocythemia ( et ) ] , adults anemia .",
    "contraindications": "• recommended : 200 mg orally daily without food . ( 2.1 ) • severe hepatic impairment ( child-pugh class c ) : reduce starting dose 150 mg orally daily . ( 2.3 )",
    "warningsAndPrecautions": "ojjaara ( momelotinib ) tablets available follows : table 6 : ojjaara presentations ndc number strength description tablets per bottle ndc 81864-103-30 100 mg round-shaped brown film-coated tablet “ ” one side “ 100 ” side . 30 ndc 81864-102-30 150 mg triangular-shaped brown film-coated tablet “ ” one side “ 150 ” side . 30 ndc 81864-101-30 200 mg capsule-shaped brown film-coated tablet “ ” one side “ 200 ” side . 30 store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . dispense patient original bottle . store original bottle protect moisture . replace cap securely time opening . discard desiccant .",
    "adverseReactions": "none .",
    "indications_original": "OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.",
    "contraindications_original": "• Recommended dosage: 200 mg orally once daily with or without food. ( 2.1 ) • Severe hepatic impairment (Child-Pugh Class C): Reduce the starting dose to 150 mg orally once daily. ( 2.3 )",
    "warningsAndPrecautions_original": "OJJAARA (momelotinib) tablets are available as follows:\n                  \n                     Table 6: OJJAARA Presentations\n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 NDC Number\n                              \n                           \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Description\n                              \n                           \n                           \n                              \n                                 Tablets per Bottle\n                              \n                           \n                        \n                        \n                           \n                              NDC 81864-103-30\n                           \n                           \n                              100 mg\n                           \n                           \n                              Round-shaped brown film-coated tablet with “M” on one side and “100” on the other side.\n                           \n                           \n                              30\n                           \n                        \n                        \n                           \n                              NDC 81864-102-30\n                           \n                           \n                              150 mg\n                           \n                           \n                              Triangular-shaped brown film-coated tablet with “M” on one side and “150” on the other side.\n                           \n                           \n                              30\n                           \n                        \n                        \n                           \n                              NDC 81864-101-30\n                           \n                           \n                              200 mg\n                           \n                           \n                              Capsule-shaped brown film-coated tablet with “M” on one side and “200” on the other side.\n                           \n                           \n                              30\n                           \n                        \n                     \n                  \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].\n                  Dispense to patient in original bottle only. Store in original bottle to protect from moisture. Replace cap securely each time after opening. Do not discard desiccant.",
    "adverseReactions_original": "None."
}